Completed PHASE4 INTERVENTIONAL 2-arm NCT00446485

Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency

Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment

Sponsor: Milsing d.o.o.

Conditions Cerebrovascular Insufficiency Mild Cognitive Impairment

Interventions Ginkgo Biloba standardized extract 24/6 Ginkgo biloba standardized extract 24/6 placebo

Updated 5 times since 2017 Last updated: Sep 24, 2015 Started: May 31, 2007 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Cerebrovascular Insufficiency and Mild Cognitive Impairment, this trial is completed. The trial is conducted by Milsing d.o.o. and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Milsing d.o.o.

Data source: Milsing d.o.o.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zagreb, Croatia